Meningococcal vaccine group B OMV (NZ) - GlaxoSmithKline/NIPH
Alternative Names: MeNZB; New Zealand candidate vaccine (NZ98/254); New Zealand epidemic strain meningococcal B OMV vaccineLatest Information Update: 02 Oct 2021
At a glance
- Originator Norwegian Institute of Public Health; Novartis
- Developer GlaxoSmithKline; Novartis; University Hospitals Bristol NHS Foundation Trust
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Meningococcal group B infections
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 08 Feb 2005 A clinical study has been added to the Bacterial Infections immunogenicity section
- 11 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections immunogenicity and adverse events section